Clinical Trial Update: A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pertuzumab and trastuzumab subcutaneous in combination with a taxane for HER2-positive metastatic breast cancer has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-07-23